FourThought Financial Partners LLC Increases Stock Position in Medtronic PLC $MDT

FourThought Financial Partners LLC lifted its holdings in Medtronic PLC (NYSE:MDT) by 2.4% during the second quarter, Holdings Channel reports. The institutional investor owned 179,751 shares of the medical technology company’s stock after acquiring an additional 4,248 shares during the quarter. Medtronic makes up approximately 1.5% of FourThought Financial Partners LLC’s investment portfolio, making the stock its 13th biggest position. FourThought Financial Partners LLC’s holdings in Medtronic were worth $15,669,000 at the end of the most recent quarter.

A number of other large investors also recently bought and sold shares of MDT. SlateStone Wealth LLC boosted its stake in Medtronic by 6.2% during the second quarter. SlateStone Wealth LLC now owns 59,284 shares of the medical technology company’s stock worth $5,168,000 after acquiring an additional 3,442 shares in the last quarter. Laurel Wealth Advisors LLC lifted its holdings in shares of Medtronic by 8,779.8% during the second quarter. Laurel Wealth Advisors LLC now owns 1,069,664 shares of the medical technology company’s stock valued at $93,243,000 after purchasing an additional 1,057,618 shares during the last quarter. Aviso Financial Inc. grew its stake in shares of Medtronic by 3.6% in the 2nd quarter. Aviso Financial Inc. now owns 27,551 shares of the medical technology company’s stock worth $2,402,000 after buying an additional 966 shares during the last quarter. Kimelman & Baird LLC grew its stake in shares of Medtronic by 2,141.4% in the 2nd quarter. Kimelman & Baird LLC now owns 138,991 shares of the medical technology company’s stock worth $12,116,000 after buying an additional 132,790 shares during the last quarter. Finally, Steward Partners Investment Advisory LLC increased its position in Medtronic by 6.5% during the 2nd quarter. Steward Partners Investment Advisory LLC now owns 267,945 shares of the medical technology company’s stock valued at $23,357,000 after buying an additional 16,265 shares in the last quarter. 82.06% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling

In other Medtronic news, EVP Harry Skip Kiil sold 8,605 shares of the stock in a transaction that occurred on Wednesday, September 3rd. The shares were sold at an average price of $91.58, for a total value of $788,045.90. Following the transaction, the executive vice president directly owned 35,615 shares in the company, valued at approximately $3,261,621.70. This trade represents a 19.46% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Corporate insiders own 0.26% of the company’s stock.

Medtronic Trading Up 2.1%

NYSE:MDT opened at $103.36 on Tuesday. The company has a market cap of $132.58 billion, a PE ratio of 28.47, a price-to-earnings-growth ratio of 2.42 and a beta of 0.77. The company has a current ratio of 2.01, a quick ratio of 1.50 and a debt-to-equity ratio of 0.54. The company has a 50 day simple moving average of $95.24 and a two-hundred day simple moving average of $91.14. Medtronic PLC has a 12 month low of $79.29 and a 12 month high of $103.70.

Medtronic (NYSE:MDT) last released its quarterly earnings results on Tuesday, November 18th. The medical technology company reported $1.36 EPS for the quarter, beating the consensus estimate of $1.31 by $0.05. Medtronic had a net margin of 13.63% and a return on equity of 14.61%. The firm had revenue of $8.96 billion during the quarter, compared to analyst estimates of $8.86 billion. During the same quarter in the prior year, the firm earned $1.26 EPS. The business’s revenue for the quarter was up 6.6% compared to the same quarter last year. Medtronic has set its FY 2026 guidance at 5.620-5.660 EPS. Research analysts forecast that Medtronic PLC will post 5.46 earnings per share for the current year.

Analyst Ratings Changes

MDT has been the subject of several recent analyst reports. Argus lifted their price target on Medtronic from $105.00 to $115.00 and gave the stock a “buy” rating in a research report on Tuesday, August 26th. Wall Street Zen raised shares of Medtronic from a “hold” rating to a “buy” rating in a report on Saturday. Royal Bank Of Canada increased their price target on shares of Medtronic from $111.00 to $118.00 and gave the company an “outperform” rating in a report on Wednesday, November 19th. Leerink Partners set a $120.00 price objective on shares of Medtronic and gave the stock an “outperform” rating in a report on Wednesday, November 19th. Finally, Citigroup upped their price objective on Medtronic from $101.00 to $112.00 and gave the company a “buy” rating in a research report on Tuesday, October 7th. One research analyst has rated the stock with a Strong Buy rating, thirteen have issued a Buy rating and twelve have issued a Hold rating to the stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $109.72.

About Medtronic

Medtronic plc develops, manufactures, and sells device-based medical therapies to healthcare systems, physicians, clinicians, and patients worldwide. Its Cardiovascular Portfolio segment offers implantable cardiac pacemakers, cardioverter defibrillators, and cardiac resynchronization therapy devices; cardiac ablation products; insertable cardiac monitor systems; TYRX products; and remote monitoring and patient-centered software.